Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2017 08:00 ET | Source: Lipocine, Inc.

Lipocine to Present at 29th Annual ROTH Conference

SALT LAKE CITY, March 06, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
February 15, 2017 08:00 ET | Source: Lipocine, Inc.

Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer

SALT LAKE CITY, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company focused on developing innovative oral treatment alternatives for use in men’s and...
January 09, 2017 07:00 ET | Source: Lipocine, Inc.

Lipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth

Critical Phase 3 study design input received from U.S. Food and Drug Administration (“FDA”): Agreed to a randomized open-label, two-arm clinical study to include a LPCN 1107 arm and a comparator...
January 05, 2017 08:00 ET | Source: Lipocine, Inc.

Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate

SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced plans to initiate a dosing flexibility (“DF”) study in addition to...
December 05, 2016 08:00 ET | Source: Lipocine, Inc.

Lipocine to Initiate Dosing Validation Study for LPCN 1021, Oral Testosterone Replacement Product Candidate

SALT LAKE CITY, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced it plans to initiate a dosing validation study after receiving...
November 08, 2016 08:00 ET | Source: Lipocine, Inc.

Lipocine Announces Financial and Operational Results for the Third Quarter of 2016

SALT LAKE CITY, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended September...
November 07, 2016 08:00 ET | Source: Lipocine, Inc.

Lipocine Announces Issuance of US Patent 9,480,690

SALT LAKE CITY, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today reported the United States Patent and Trademark Office (“USPTO”) issued...
October 17, 2016 08:00 ET | Source: Lipocine, Inc.

Lipocine Completes Post Action Meeting With FDA for LPCN 1021 New Drug Application

SALT LAKE CITY, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced the completion of a Post Action meeting with the U.S. Food and...
October 07, 2016 14:32 ET | Source: Lipocine, Inc.

Lipocine Wins Dismissal of Patent Infringement Lawsuit Related to LPCN 1021

SALT LAKE CITY, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that U.S. District Court in Delaware granted our motion to dismiss...
September 26, 2016 08:00 ET | Source: Lipocine, Inc.

Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy

Once-daily dose identified for the pivotal Phase 3 studyWell tolerated with no drug-related severe or serious adverse events reported SALT LAKE CITY, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Lipocine...